Doctor Who Fought 8 Years for Children’s Lives Now Hit with Legal Notice
Hyderabad paediatrician Dr. Sivaranjani Santosh, who advocated for clearer ORS labelling, receives legal notice from companies linked to Kenvue and Johnson & Johnson.
Table of contents [Show]
FDA Approves New Treatment for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved a new treatment developed by Johnson & Johnson for a type of blood cancer under its accelerated review program. The approval provides a new treatment option for patients with relapsed or refractory multiple myeloma, particularly those whose disease has returned after initial therapy. The targeted therapy aims to improve outcomes while potentially causing fewer side effects compared to traditional treatment approaches.
Newly Approved Drug Combination
The FDA approved a combination of TECVAYLI and DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma who have already received at least one prior line of therapy. Patients eligible for this treatment typically would have been previously treated with both a proteasome inhibitor and an immunomodulatory agent.
TECVAYLI is a bispecific antibody that targets BCMA on myeloma cells, while DARZALEX FASPRO is a subcutaneous monoclonal antibody targeting CD38. Together, these drugs work to help the immune system recognize and destroy cancer cells more effectively.
Why This Approval Is Significant
This approval is considered significant because it introduces a potentially new standard of care as early as the second line of treatment for multiple myeloma. Approximately 40 percent of patients with multiple myeloma experience relapse after their initial therapies. The newly approved combination therapy offers a promising option for these patients who require additional treatment strategies.
Clinical Trial Evidence Behind the Approval
The approval was supported by results from the Phase 3 MajesTEC-3 Trial. The study demonstrated strong clinical benefits when compared with currently used standard regimens such as daratumumab combined with pomalidomide and dexamethasone or combinations based on bortezomib.
Key findings from the trial showed an 83 percent reduction in the risk of disease progression or death compared with standard treatment options. The study also reported statistically significant improvements in both progression free survival and overall survival.
Long term follow up data indicated durable responses, with approximately 83.3 percent of patients still alive after three years in related long term analyses.
How the Therapy Works
The two drugs act together to stimulate the immune system to attack cancer cells. TECVAYLI binds to B cell maturation antigen (BCMA) present on myeloma cells, while DARZALEX FASPRO targets the CD38 protein on these cancer cells. This dual targeting approach helps immune cells identify and eliminate malignant plasma cells more effectively.
Fast Track Review and Approval Timeline
The treatment regimen received a national priority voucher in late 2025, allowing the application to go through an expedited regulatory review. This accelerated pathway significantly shortened the usual approval timeline and led to full FDA approval in early March 2026.
Impact on Patients with Multiple Myeloma
Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow and often requires long term management. The new therapy adds to Johnson and Johnson’s expanding hematology portfolio and builds on earlier approvals of TECVAYLI as a monotherapy. For patients with relapsed disease, this combination therapy may offer improved survival outcomes and an additional treatment option in the evolving management of multiple myeloma.
